[NY-ESO-1 and cancer immunotherapy].
NY-ESO-1 is an important member of cancer-testis antigen family and is widely distributed among many cancer types. As a tumor-specific antigen with the strongest immunogenicity so far identified, it can induce spontaneous antibody and T-cell responses in patients with NY-ESO-1-positive tumors. Therefore, it has been a good vaccine candidate in the immunotherapy against many malignancies. This article reviews the recent research advances in NY-ESO-1 and its relevant vaccines.
Peng
Ji-run
JR
Center of Hepatobiliary Surgery, Peking University People's Hospital, Beijing 100044, China.
Leng
Xi-sheng
XS
D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D009369:Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy*
D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D008565:Membrane Proteins